Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia

References

• Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in ckd: systematic review and meta-analysis. Am J Kidney Dis. 2008;52(5):897–906
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int. 2012;2:279–335
   Web of Science ®Google Scholar
• Wish JB. Past, present and future of chronic kidney disease anemia management in the United States. Adv Chronic Kidney Dis. 2009;16(2):101–108
   PubMed Web of Science ®Google Scholar
• St. Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994–2002). Am J Kidney Dis. 2005;46(4):650–660
   PubMed Web of Science ®Google Scholar
• Auerbach M, Winchester J, Wahab A, et al. A randomized trial of three iron dextran infusion methods for anemia in epo-treated dialysis patients. Am J Kidney Dis. 1998;31(1):81–16
   PubMed Web of Science ®Google Scholar
• Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol. 2006;26(5):445–454
   PubMed Web of Science ®Google Scholar
• Charytan C, Qunibi W, Bailie GR, Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract. 2005;100(3):c55–c62
   PubMedGoogle Scholar
• Leavitt M. Secretary of health and human services. Report to Congress: A design for a bundled end stage renal disease prospective payment system; 2008
   Google Scholar
• Yee J, Besarab A. Iron sucrose: the oldest iron therapy becomes new. Am J Kidney Dis. 2002;40(6):1111–1121
   PubMed Web of Science ®Google Scholar
• Ganguli A, Kohli HS, Khullar M, Lal Gupta K, Jha V, Sakhuja V. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail. 2009;31(2):106–110
   PubMed Web of Science ®Google Scholar
• Auerbach M, Al Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int. 2008;73(5):528–530
   PubMed Web of Science ®Google Scholar
• Sav T, Tokgoz B, Sipahioglu MH, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail. 2007;29(4):423–426
   PubMed Web of Science ®Google Scholar
• Anirban G, Kohli HS, Jha V, et al. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail. 2008;30(6):629–638
   PubMed Web of Science ®Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21(2):378–382
   PubMed Web of Science ®Google Scholar
• Ubel PA. Pricing Life: Why it's Time for Health Care Rationing. Cambridge, MA: MIT Press; 2000
   Google Scholar
• Fishbane S. Safety in iron management. Am J Kidney Dis. 2003;41:18–26
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H. Intravenous ironin oncology. J Natl Compr Canc Netw. 2008;6(6):585–592
   PubMedGoogle Scholar
• Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996;28(4):529–534
   PubMed Web of Science ®Google Scholar
• Pizzi LT. Economic considerations in a changing anemia environment. Am J Kidney Dis. 2008;52:S29–S33
   PubMed Web of Science ®Google Scholar
• Coyne DW, Kapoian T, Suki W, et al.; DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to iv iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007;18(3):975–984
   PubMed Web of Science ®Google Scholar
• Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis. 1995;26(1):41–46
   PubMed Web of Science ®Google Scholar
• Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis. 2001;38(4):803–812
   PubMed Web of Science ®Google Scholar
• Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):386–393
   PubMed Web of Science ®Google Scholar
• Singh A, Patel T, Hertel J, Bernardo M, Kausz A, Brenner L. Safety of ferumoxytol in patients with anemia and CKD. Am J Kidney Dis. 2008;52(5):907–915
   PubMed Web of Science ®Google Scholar
• Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol. 2008;19(8):1599–1605
   PubMed Web of Science ®Google Scholar
• Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(5):1599–1607
   PubMed Web of Science ®Google Scholar
• Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004;65:2279–2289
   PubMed Web of Science ®Google Scholar
• Agarwal R. On the nature of proteinuria with acute renal injury in patients with chronic kidney disease. Am J Physiol Renal Physiol. 2005;288:F265–F271
   PubMed Web of Science ®Google Scholar
• Agarwal R. Proinflammatory effects of iron sucrose in chronic kidney disease. Kidney Int. 2006;69:1259–1263
   PubMed Web of Science ®Google Scholar
• Zager RA. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int. 2005;68:1533–1542
   PubMed Web of Science ®Google Scholar